Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
10:05am, Wednesday, 24'th Sep 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Novo To Contact Him Directly To Discuss Their Options If you suffe
NVO Deadline: NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit
05:14pm, Tuesday, 23'rd Sep 2025
NEW YORK , Sept. 23, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between May 7, 2025 and July 28, 202
NEW YORK, Sept. 23, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between May 7, 2025 and July 28,
BENSALEM, Pa., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded
LOS ANGELES, Sept. 23, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded
Pfizer's Metsera buy raises competitive heat for Novo Nordisk
10:47am, Tuesday, 23'rd Sep 2025
UBS has warned that Pfizer Inc's (NYSE:PFE, ETR:PFE) $7.3 billion acquisition of Metsera will sharpen competition for Novo Nordisk (NYSE:NVO) in the fast-growing obesity drug market, particularly tow
NEW YORK , Sept. 23, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO).
Mounjaro, Ozempic: Obesity market shifting to portfolio play as GLP-1 innovation peaks, says leading bank
09:36am, Tuesday, 23'rd Sep 2025
Goldman Sachs analysts say the obesity drug market is entering a new phase where breadth of treatment options, rather than reliance on a single blockbuster, will determine long-term winners. Wrapping
Novo Nordisk (NVO) Stock Sinks As Market Gains: Here's Why
06:46pm, Monday, 22'nd Sep 2025
In the most recent trading session, Novo Nordisk (NVO) closed at $60.71, indicating a -1.12% shift from the previous trading day.
PHILADELPHIA , Sept. 22, 2025 /PRNewswire/ -- Berger Montague PC is investigating potential securities fraud claims on behalf of investors of Novo Nordisk A/S.
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 30, 2025 in Novo Lawsuit – NVO
03:52pm, Monday, 22'nd Sep 2025
NEW YORK, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit.
LLY & NVO Lead "Very Early Stages" of GLP-1 Market, PFE Reenters
03:10pm, Monday, 22'nd Sep 2025
Scott Zari says we're in the "very early stages" of the weight loss market. He points to Eli Lilly (LLY) as the market leader but notes Novo Nordisk (NVO) as a strong competitor, especially as it deve
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
10:21am, Monday, 22'nd Sep 2025
Novo Nordisk (NVO) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
NEW YORK , Sept. 22, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO).
3 Dirt-Cheap Stocks to Buy Right Now
08:30am, Monday, 22'nd Sep 2025
The major market indexes are bumping against all-time highs. It's not surprising, therefore, that many stocks are trading at steep valuations.
